Literature DB >> 10699708

Nanosuspensions of poorly soluble drugs--reproducibility of small scale production.

M J Grau1, O Kayser, R H Müller.   

Abstract

The major problem of many newly developed pharmaceutical drugs is their poor solubility in water and simultaneously in organic media. To solve these problems formulation as nanosuspensions is an attractive alternative. During the drug development process screening for an optimal formulation by homogenisation is essential. Time and cost effective production in an initial phase of R&D can be conducted on lab scale by using the Micron Lab 40 in its discontinuous version. In this report reproducibility of small scale production parameters (particle size, size distribution, content of microparticles) was exemplary studied for the drug RMKP22.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699708     DOI: 10.1016/s0378-5173(99)00411-1

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Micronization of insulin by high pressure homogenization.

Authors:  Angelika Maschke; Nadia Calí; Bernhard Appel; Josef Kiermaier; Torsten Blunk; Achim Göpferich
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 3.  The evolving landscape of drug products containing nanomaterials in the United States.

Authors:  Sheetal R D'Mello; Celia N Cruz; Mei-Ling Chen; Mamta Kapoor; Sau L Lee; Katherine M Tyner
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

4.  Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization.

Authors:  Nilesh S Saindane; Kunal P Pagar; Pradeep R Vavia
Journal:  AAPS PharmSciTech       Date:  2012-12-20       Impact factor: 3.246

5.  Pyrimethamine nanosuspension with improved bioavailability: in vivo pharmacokinetic studies.

Authors:  Vividha Dhapte; Vivek Kadam; Varsha Pokharkar
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

6.  Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.

Authors:  Ildiko R Dunay; Markus M Heimesaat; Faris Nadiem Bushrab; Rainer H Müller; Hartmut Stocker; Keikawus Arasteh; Michael Kurowski; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Use of Flory-Huggins Interaction Parameter and Contact Angle Values to Predict the Suitability of the Drug-Polymer System for the Production and Stability of Nanosuspensions.

Authors:  Rakesh K Patel; Sriramakamal Jonnalagadda; Pardeep K Gupta
Journal:  Pharm Res       Date:  2022-05-03       Impact factor: 4.200

8.  Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery.

Authors:  Po-Chang Chiang; Jason W Alsup; Yurong Lai; Yiding Hu; Bruce R Heyde; David Tung
Journal:  Nanoscale Res Lett       Date:  2009-01-06       Impact factor: 4.703

9.  Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride.

Authors:  C G Thanos; Z Liu; J Reineke; E Edwards; E Mathiowitz
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

10.  Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity.

Authors:  Hongxing Wang; Qigui Li; Sean Reyes; Jing Zhang; Lisa Xie; Victor Melendez; Mark Hickman; Michael P Kozar
Journal:  Malar Res Treat       Date:  2013-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.